https://www.selleckchem.com/pr....oducts/Rapamycin.htm
99, 95% CI 1.53-5.89, P=0.002), but not in patients with glioblastoma (HR 1.26, 95% CI 0.76-2.08, P=0.47; P for subgroup difference = 0.03). Results were not statistically different between subgroups according to patient ethnicity, sample size, CD44 detection method, CD44 cutoff, HR estimation, univariate or multivariate analysis, or median follow-up durations (P-values for subgroup difference all 0.1. CONCLUSION Higher tumor expression of CD44 may predict poor survival in patients with glioma, particularly in those with WHO sta
Like
Comment
Share
